June 17th, 2019: “EURETINA-Brief”© Issue No. 194

by Dr. Gearóid Tuohy

 

Dear EURETINA Members,

 

A very warm welcome to the June 17th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”.  EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is designed to accommodate the very busy schedules of all our members by providing them with a short overview of some new developments and announcements in our field over recent weeks.

 

As in previous issues we have incorporated a feedback section where you can comment on any of the news items or articles under discussion and we very much welcome all contributions.  Previous articles and issues can be found in the archive section on this website.

 

The current issue highlights a number of research activities, clinical / regulatory milestones, and market / business developments in our field, including a drug delivery approach for a thermoresponsive polymer for a sustained anti-VEGF treatment for AMD; clinical research for systematic reviews and meta-analysis focusing on cn-AMD, DMO, RVO-MO and m-CNV, and;  an announcement from Alkahest’s oral small molecule drug aims to reporting on a Phase IIa study for age-related macular degeneration.

 

Finally, our feature bio-ophthalmology article reports on the need for expert research scientists to support the evaluation of new drug approvals for novel technologies, including retinal stem cell and gene therapies. The pace of new technology and novel medical treatments has reached a point at which regulators and assessors require additional expert evaluation in reviewing and assessing marketing authorizations.  Specialist researchers in fields such as genetics, stem cell biology, gene editing and others, are required to assist regulators assess and evaluate new therapies that rapidly progress from academic research to clinical application.  Recent examples include on the submission of a marketing application to the European Medicines Agency for Investigational “LUXTURNA” (voretigene neparvovec).  The application arises from several years research involving academic, regulatory and industry experts to devise a therapy to treat RPE-65 related retinopathies.

 

As always, your increased interaction within the EURETINA web community serves to expand your professional network and keep you up to date with the latest initiatives, activities and research in your field. Our hope is that such cross-fertilisation in an active web-based platform, including our LinkedIn page, will lead to increased collaborative opportunities and ultimately to improved patient care. All readers are invited to submit comments or responses to any of the stories featured and we look forward to hearing from you over the coming month.

 

Best wishes,

Dr. Gearóid Tuohy, EURETINA

5 thoughts on “June 17th, 2019: “EURETINA-Brief”© Issue No. 194”

  1. 먹튀폴리스는 먹튀검증커뮤니티로써 꽁머니
    제공은 물론, 먹튀사이트의 먹튀검증을 위한
    검증사이트입니다. 먹튀폴리스 먹튀검증커뮤니티를 통해 신규 먹튀사이트
    정보와 기존 토토사이트의 철저한 검증으로 먹튀없는 시대를 만들어가고 있습니다.

    먹튀검증 먹튀폴리스를 사랑하는 여러분의 많은 호응바랍니다.

Leave a Reply

Your email address will not be published.